Microbial presence in gliomas raises questions about cancer-type-specific intratumoral microbiota, emphasizing the need for rigorous validation (ref: Morad doi.org/10.1038/s41591-025-03957-4/)
Monocyte and macrophage heterogeneity in glioblastoma is crucial for tumor progression, with implications for targeted therapies (ref: Li doi.org/10.2147/OTT.S553018/)
MCTP2 is identified as a key regulator in immune suppression and drug resistance in glioblastoma, suggesting new therapeutic targets (ref: Chen doi.org/10.1007/s10142-025-01738-3/)
Spatial transcriptomics reveals mechanisms of resistance to neoadjuvant therapies in glioblastoma, highlighting the need for novel strategies (ref: Du doi.org/10.1186/s13073-025-01553-2/)
High-risk glioblastoma groups show increased M2-like macrophage infiltration and decreased CD8 T cell presence, indicating immune evasion (ref: Liu doi.org/10.1186/s12967-025-06918-0/)
ADGRG6 is a potential prognostic biomarker in glioblastoma, influencing immune responses and tumor microenvironment dynamics (ref: Zhu doi.org/10.1016/j.ijbiomac.2025.149128/)
Innovative integration of MALDI-MSI and spatial transcriptomics enhances spatial resolution in glioblastoma research (ref: Hendriks doi.org/10.1038/s41598-025-26735-1/)
Understanding GPNMB and MCTP2 roles in therapeutic resistance is critical for developing effective glioblastoma treatments (ref: Du doi.org/10.1186/s13073-025-01553-2/)